Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations

被引:151
作者
Evans, DGR [1 ]
Trueman, L
Wallace, A
Collins, S
Strachan, T
机构
[1] St Marys Hosp, Dept Med Genet, Manchester M13 0JH, Lancs, England
[2] Univ Newcastle Upon Tyne, Dept Human Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
关键词
neurofibromatosis type 2; somatic mosaicism; mutation; vestibular schwannoma;
D O I
10.1136/jmg.35.6.450
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Blood samples from 125 unrelated families with classical type 2 neurofibromatosis (NF2) with bilateral vestibular schwannomas have been analysed for mutations in the NF2 gene. A further 17 families fulfilling modified criteria for NF2 have also been analysed. Causative mutations have been identified in 54 (43%) classical families and six (35%) of those fulfilling modified criteria. Forty-two cases from 38 families with truncating mutations had an average ape at onset of symptoms of 19 years and diagnosis at 22.4 years. Fifty-one cases from 16 families with splice site mutations (15 from six), missense mutations (18 from six), and large deletions (18 from five) had an average age of onset of 27.8 years and at diagnosis of 33.4 years. Subjects with truncating mutations were significantly more likely to have symptoms before 20 years of age (p<0.001) and to develop at least two symptomatic CNS tumours in addition to vestibular schwannoma before 30 years (p<0.001). There were also significantly fewer multigenerational families with truncating mutations. Four further truncating mutations were in mosaic form and were associated with milder disease than other similar mutations. This large study has confirmed the previous impression that truncating mutations are associated with severe disease, but caution has to be exercised in using mutation type to predict disease course.
引用
收藏
页码:450 / 455
页数:6
相关论文
共 27 条
[1]  
Baser M., 1995, American Journal of Human Genetics, V57, pA54
[2]  
BILJSMA EK, 1997, J MED GENET, V34, P934
[3]   GERMLINE MUTATIONS IN THE NEUROFIBROMATOSIS TYPE-2 TUMOR-SUPPRESSOR GENE [J].
BOURN, D ;
CARTER, SA ;
MASON, S ;
EVANS, DGR ;
STRACHAN, T .
HUMAN MOLECULAR GENETICS, 1994, 3 (05) :813-816
[4]  
BOURN D, 1994, AM J HUM GENET, V55, P69
[5]  
BOURN D, 1995, HUM GENET, V95, P572
[6]  
BOURN D, 1995, HUM GENET, V95, P712
[7]   METHODS FOR COMPARING EVENT RATES IN INTERVENTION STUDIES WHEN THE UNIT OF ALLOCATION IS A CLUSTER [J].
DONNER, A ;
KLAR, N .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1994, 140 (03) :279-289
[8]   DIAGNOSTIC ISSUES IN A FAMILY WITH LATE-ONSET TYPE-2 NEUROFIBROMATOSIS [J].
EVANS, DGR ;
BOURN, D ;
WALLACE, A ;
RAMSDEN, RT ;
MITCHELL, JD ;
STRACHAN, T .
JOURNAL OF MEDICAL GENETICS, 1995, 32 (06) :470-474
[9]   TYPE-2 NEUROFIBROMATOSIS - THE NEED FOR SUPRAREGIONAL CARE [J].
EVANS, DGR ;
RAMSDEN, R ;
HUSON, SM ;
HARRIS, R ;
LYE, R ;
KING, TT .
JOURNAL OF LARYNGOLOGY AND OTOLOGY, 1993, 107 (05) :401-406
[10]   Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: A clinical and molecular study [J].
Evans, DGR ;
Mason, S ;
Huson, SM ;
Ponder, M ;
Harding, AE ;
Strachan, T .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1997, 62 (04) :361-366